Even though oncology segment revenue inched up just 1 percent year over year, the firm lifted full-year expectations slightly ...

In results from a Phase Ib study, Hernexeos showed a 75 percent response rate and more than half of patients responded for at least six months.

The assay, developed by ValiRx subsidiary Inaphaea, uses patient-derived cells to predict sensitivity to drugs.

NXC-201 is currently being evaluated in AL amyloidosis within a Phase Ib/II trial, but Immix plans to test it in other, undisclosed serious diseases.

NEW YORK – ProteinQure said on Thursday that the US Food and Drug Administration and Health Canada cleared it to begin a Phase I trial of its lead candidate, the peptide-drug conjugate PQ203, in ...

During a Q2 earnings call, the firm discussed progress on an FGFR2b antibody, a subcutaneous version of Blincyto, and ...

The firm recently had a successful end-of-Phase II meeting with the FDA, in which the agency provided feedback into a Phase III trial design.

In a combined analysis of patients from five open-label trials, 22 percent responded to the protease activator, the first approved treatment for the rare disease.

Researchers at Stanford and St. Jude aim to bring PGx resources under one new umbrella and accelerate the discipline's ...

Most of its precision oncology products, including Lorbrena, Braftovi, Mektovi, and Talzenna, posted double-digit increases ...

At AAIC, Lilly highlighted benefits of being able to stop Kisunla, while Eisai made a case for subcutaneous Leqembi, which is ...

Patients must express PPARG in at least 60 percent of tumor cells to enroll in the trial and receive the investigational drug.